drugset / Trial / NCT05555641
Efficacy and Safety of Nafamostat Mesylate for VV-ECMO Anticoagulation
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study was to compare the efficacy and safety of nafamostat mesylate and unfractionated heparin during ECMO anticoagulation in critically ill patients.
Timeline
- Start
- 2022-12-20
- Primary completion
- 2024-10-01
- Completion
- 2024-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Heparin | Other / unclassified | — | — |
| Subject | Nafamostat | Small molecule | — | — |
Indications
No indication recorded.